Vol. 3 No. 4 (2023)
Reimbursement Reviews

Pembrolizumab (Keytruda)

decorative image

Published April 25, 2023

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses pembrolizumab; powder for solution for infusion 50 mg or solution for infusion 100 mg/4 mL vial IV infusion over 30 minutes.
  • Indication: For the treatment of adult patients with unresectable or metastatic microsatellite instability–high or mismatch repair–deficient endometrial cancer whose tumours have progressed following prior therapy and who have no satisfactory alternative treatment options, as monotherapy.